Helius Medical Technologies, Inc. (HSDT)
NASDAQ: HSDT · Real-Time Price · USD
0.2955
+0.0005 (0.17%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Company Description
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma.
The company’s product is Portable Neuromodulation Stimulator, a non- implantable medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.
The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.
Helius Medical Technologies, Inc.
| Country | United States |
| Founded | 2014 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Dane Andreeff |
Contact Details
Address: 642 Newtown Yardley Road, Suite 100 Newtown, Pennsylvania 18940 United States | |
| Phone | 215 944 6100 |
| Website | heliusmedical.com |
Stock Details
| Ticker Symbol | HSDT |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001610853 |
| CUSIP Number | 42328V504 |
| ISIN Number | US42328V8019 |
| Employer ID | 36-4787690 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Dane Carl Andreeff | President, Chief Executive Officer and Director |
| Jeffrey S. Mathiesen CPA | Chief Financial Officer, Treasurer, Secretary and Director |
| Dr. Antonella Favit-Van Pelt M.D., Ph.D. | Chief Medical Officer |
| Lawrence Picciano | Senior Vice President of Engineering, Quality and Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 22, 2025 | 8-K | Current Report |
| Apr 4, 2025 | 8-K | Current Report |
| Apr 4, 2025 | ARS | Filing |
| Mar 27, 2025 | EFFECT | Notice of Effectiveness |
| Mar 26, 2025 | 424B5 | Filing |
| Mar 25, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 25, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Mar 25, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 25, 2025 | 10-K | Annual Report |